DIPG
MCID: DFF037
MIFTS: 42

Diffuse Intrinsic Pontine Glioma (DIPG)

Categories: Neuronal diseases, Rare diseases

Aliases & Classifications for Diffuse Intrinsic Pontine Glioma

MalaCards integrated aliases for Diffuse Intrinsic Pontine Glioma:

Name: Diffuse Intrinsic Pontine Glioma 52 58 6 17 71
Dipg 52 58
Infiltrative Brainstem Glioma 52

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Orphanet 58 ORPHA497188
UMLS 71 C2986658

Summaries for Diffuse Intrinsic Pontine Glioma

MalaCards based summary : Diffuse Intrinsic Pontine Glioma, also known as dipg, is related to glioma and juvenile pilocytic astrocytoma. An important gene associated with Diffuse Intrinsic Pontine Glioma is BRCA2 (BRCA2 DNA Repair Associated), and among its related pathways/superpathways are ERK Signaling and Activation of cAMP-Dependent PKA. The drugs Etoposide and Lomustine have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pons.

Wikipedia : 74 A diffuse intrinsic pontine glioma (DIPG) is a tumour located in the pons (middle) of the brain stem.... more...

Related Diseases for Diffuse Intrinsic Pontine Glioma

Diseases related to Diffuse Intrinsic Pontine Glioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 72)
# Related Disease Score Top Affiliating Genes
1 glioma 31.1 H3C1 H3-3A BRCA2
2 juvenile pilocytic astrocytoma 30.2 H3-3B H3-3A
3 grade iii astrocytoma 30.0 H3-3B H3-3A
4 fibrillary astrocytoma 29.5 H3C2 H3-3B H3-3A
5 glioblastoma multiforme 28.9 H3C2 H3C1 H3-3B H3-3A BRCA2
6 brain stem glioma 28.6 H3C2 H3C1 H3-3B H3-3A
7 glial tumor 11.3
8 brain cancer 10.6
9 astrocytoma 10.6
10 hydrocephalus 10.4
11 neutropenia 10.4
12 cranial nerve palsy 10.4
13 brain tumor, childhood 10.4
14 ataxia and polyneuropathy, adult-onset 10.3
15 rare surgical neurologic disease 10.3
16 retinoblastoma 10.3
17 respiratory failure 10.3
18 facial paralysis 10.3
19 familial retinoblastoma 10.3
20 lymphopenia 10.3
21 alopecia 10.3
22 fibrodysplasia ossificans progressiva 10.1
23 glioma susceptibility 1 10.1
24 medulloblastoma 10.1
25 neurofibromatosis, type iv, of riccardi 10.1
26 hydrocephalus, congenital, 1 10.1
27 wilms tumor 5 10.1
28 exanthem 10.1
29 neonatal respiratory failure 10.1
30 obstructive hydrocephalus 10.1
31 communicating hydrocephalus 10.1
32 thrombocytopenia 10.1
33 malignant glioma 10.1
34 vaccinia 10.1
35 craniopharyngioma 10.1
36 hypokalemia 10.1
37 neuroblastoma 10.1
38 intracranial hypertension 10.1
39 47,xyy 10.1
40 subependymoma 10.1
41 high-grade astrocytoma 10.1
42 benign idiopathic neonatal seizures 10.1
43 rare tumor 10.1
44 polyploidy 10.1
45 gliomatosis cerebri 10.0
46 adult brain stem glioma 10.0 H3-3B H3-3A
47 bone giant cell sarcoma 10.0 H3-3B H3-3A
48 malignant giant cell tumor 9.9 H3-3B H3-3A
49 giant cell tumor 9.9 H3-3B H3-3A
50 telangiectatic osteogenic sarcoma 9.9 H3-3B H3-3A

Graphical network of the top 20 diseases related to Diffuse Intrinsic Pontine Glioma:



Diseases related to Diffuse Intrinsic Pontine Glioma

Symptoms & Phenotypes for Diffuse Intrinsic Pontine Glioma

Drugs & Therapeutics for Diffuse Intrinsic Pontine Glioma

Drugs for Diffuse Intrinsic Pontine Glioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 3 33419-42-0 36462
2
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
3
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
4
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
7
leucovorin Approved Phase 3 58-05-9 6006 143
8
Ifosfamide Approved Phase 3 3778-73-2 3690
9
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
10
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
11
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
12
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
13
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
14
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
15
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
16
Nimotuzumab Investigational Phase 2, Phase 3 780758-10-3, 828933-61-3
17 Immunosuppressive Agents Phase 3
18 Topoisomerase Inhibitors Phase 3
19 Antimetabolites Phase 3
20 Antirheumatic Agents Phase 3
21 Etoposide phosphate Phase 3
22 Antimitotic Agents Phase 3
23 Vitamin B Complex Phase 3
24 Vitamin B9 Phase 3
25 Folate Phase 3
26 Dermatologic Agents Phase 3
27
Isophosphamide mustard Phase 3 0
28 Folic Acid Antagonists Phase 3
29 Hormone Antagonists Phase 3
30 Calcium, Dietary Phase 3
31 Antineoplastic Agents, Hormonal Phase 3
32 glucocorticoids Phase 3
33 Hormones Phase 3
34 Antibodies, Monoclonal Phase 2, Phase 3
35 Antineoplastic Agents, Immunological Phase 2, Phase 3
36 Immunoglobulins Phase 2, Phase 3
37 Antibodies Phase 2, Phase 3
38 Anti-Infective Agents Phase 3
39 Tranquilizing Agents Phase 3
40 Neurotransmitter Agents Phase 3
41 GABA Agents Phase 3
42 Anticonvulsants Phase 3
43 Psychotropic Drugs Phase 3
44 Antimanic Agents Phase 3
45 Central Nervous System Depressants Phase 3
46 Antiparasitic Agents Phase 3
47 Anthelmintics Phase 3
48 Anti-Inflammatory Agents Phase 3
49 Anti-Inflammatory Agents, Non-Steroidal Phase 3
50 Pharmaceutical Solutions Phase 3

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Prospective Randomized Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Pediatric Diffuse Brainstem Glioma Unknown status NCT01878266 Phase 3
2 Treatment of Children and Adolescents With Diffuse Intrinsic Pontine Glioma and High Grade Glioma Unknown status NCT00278278 Phase 3 cisplatin;etoposide;ifosfamide;lomustine;methotrexate;prednisone;vincristine sulfate
3 Prospective Randomized Trial of Hypofractionated Radiotherapy Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children. Completed NCT01635140 Phase 3
4 A RANDOMIZED, MULTICENTER, PHASE IIB/IIIA STUDY OF GEMCITABINE AND THE MONOCLONAL ANTIBODY NIMOTUZUMAB (OSAG 101) VERSUS GEMCITABINE AND PLACEBO FOR THE TREATMENT OF CHEMOTHERAPY-NAIVE PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER Completed NCT00561990 Phase 2, Phase 3 Nimotuzumab
5 International Cooperative Phase III Trial of the HIT-HGG Study Group for the Treatment of High Grade Glioma, Diffuse Intrinsic Pontine Glioma, and Gliomatosis Cerebri in Children and Adolescents < 18 Years.(HIT-HGG-2013) Recruiting NCT03243461 Phase 3 Temozolomide + Valproic Acid;Temozolomide + Chloroquine
6 A Randomized Phase 3 Study of Combination Antineoplaston Therapy [Antineoplastons A10 (Atengenal) and AS2-1 (Astugenal)] Plus Radiation Therapy vs. Radiation Therapy Only in Subjects With Newly Diagnosed Diffuse, Intrinsic, Brainstem Glioma Not yet recruiting NCT02887040 Phase 3 Atengenal;Astugenal
7 A Phase I/ II Clinical Trial of MDV9300 (Pidilizumab) in Diffuse Intrinsic Pontine Glioma Unknown status NCT01952769 Phase 1, Phase 2
8 Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma Completed NCT00600054 Phase 2
9 Palliative Re-irradiation for Progressive Diffuse Intrinsic Pontine Glioma (DIPG) in Children Completed NCT01777633 Phase 1, Phase 2
10 A Phase II Study of Temozolomide in the Treatment of Children With High Grade Glioma Completed NCT00028795 Phase 2 temozolomide
11 A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System Completed NCT01751308 Phase 1, Phase 2 Cabazitaxel (XRP6258)
12 Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma: A Randomized Phase II Study of the EORTC Brain Tumor Group (EORTC Protocol 1410-BTG) Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas Completed NCT02343406 Phase 2 Lomustine;ABT-414;Temozolomide
13 A Phase II Study of Pegylated Interferon Alfa-2b (Peg-Intron (TM)) in Children With Diffuse Pontine Gliomas Completed NCT00036569 Phase 2
14 A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG) Completed NCT01514201 Phase 1, Phase 2 Temozolomide;Veliparib
15 An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-enhanced Delivery (CED) in Patients With Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated With External Beam Radiation Therapy Recruiting NCT03566199 Phase 1, Phase 2 Panobinostat Nanoparticle Formulation MTX110;Convection-Enhanced Delivery (CED)
16 An Open-label, Single-arm, Phase II Study to Evaluate Safety and Efficacy of Doxorubicin in Combination With Radiotherapy, Temozolomide and Valproic Acid in Patients With Glioblastoma Multiforme (GBM) and Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting NCT02758366 Phase 2 Doxorubicin
17 A Phase 2 Study of Dasatinib in Combination With Everolimus for Children With Gliomas Harboring PDGFR Alterations Recruiting NCT03352427 Phase 2 Dasatinib;Everolimus
18 A Safety and Pharmacokinetic Study of Single Agent REGN2810 in Pediatric Patients With Relapsed or Refractory Solid or Central Nervous System (CNS) Tumors and a Safety and Efficacy Trial of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Newly Diagnosed High-Grade Glioma, or Recurrent High-Grade Glioma Recruiting NCT03690869 Phase 1, Phase 2 REGN2810 (monotherapy);REGN2810 (maintenance)
19 Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG Recruiting NCT04049669 Phase 2 Indoximod;Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
20 Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication Recruiting NCT02233049 Phase 2 Erlotinib;Everolimus;Dasatinib
21 Phase 2 Randomized Study of RT and Reirradiation at Relapse vs Multiple Elective RT Courses With Same Concomitant CT for Newly Diagnosed Recruiting NCT03620032 Phase 2 Nimotuzumab;Vinorelbine
22 A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas Recruiting NCT01837862 Phase 1, Phase 2 Mebendazole;Vincristine;Carboplatin;Temozolomide;Bevacizumab;Irinotecan
23 A Phase 1/2 Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas Active, not recruiting NCT02750891 Phase 1, Phase 2 DSP-7888
24 A Phase 2 Study of Atengenal (A-10) and Astugenal (AS2-1) in Diffuse, Intrinsic Pontine Glioma (DIPG) Active, not recruiting NCT02742883 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
25 A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) Active, not recruiting NCT01189266 Phase 1, Phase 2 Vorinostat
26 A Phase 2 Clinical Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. Active, not recruiting NCT03257631 Phase 2 Pomalidomide;Pomalidomide
27 Phase I/II Study of Reirradiation of Recurrent or Progressive Brainstem Glioma Active, not recruiting NCT01469247 Phase 1, Phase 2
28 A Phase I/II Study of Ribociclib, a CDK4/6 Inhibitor, Following Radiation Therapy in Children With Newly Diagnosed Non-biopsied Diffuse Pontine Gliomas (DIPG) and RB+ Biopsied DIPG and High Grade Gliomas (HGG) Active, not recruiting NCT02607124 Phase 1, Phase 2 Ribociclib
29 Phase II Trial of Molecularly Determined Treatment of Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Terminated NCT01182350 Phase 2 Bevacizumab;Erlotinib;Temozolomide
30 A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children With Recurrent High-Grade Glioma, Ependymoma and Diffuse Intrinsic Pontine Glioma Terminated NCT01836549 Phase 2 imetelstat sodium
31 Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study HIT-HGG-CilMetro - A Clinical Phase II Trial of the HIT-HGG Study Group - Terminated NCT01517776 Phase 2 Cilengitide;Temozolomide
32 A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma. Terminated NCT01774253 Phase 2 Vismodegib
33 A Phase 2 Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas Harboring H3.3 or H3.1 K27M Mutation Withdrawn NCT03632317 Phase 2 Panobinostat;Everolimus
34 A Phase I Study of Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy Unknown status NCT01502917 Phase 1
35 Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children With Diffuse Intrinsic Pontine Glioma Completed NCT00996723 Phase 1 vandetanib and dasatinib
36 Intra-arterial Chemotherapy for the Treatment of Progressive Diffuse Intrinsic Pontine Gliomas (DIPG). Completed NCT01688401 Phase 1 Melphalan hydrochloride
37 Platelet Derived Growth Factor Receptor (PDGFR) Inhibitor Crenolanib in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma Including Diffuse Intrinsic Pontine Glioma Completed NCT01393912 Phase 1 Crenolanib
38 Phase I Study of the Combination of Crizotinib and Dasatinib in Pediatric Research Participants With Diffuse Pontine Glioma (DIPG) and High-Grade Glioma (HGG) Completed NCT01644773 Phase 1 Crizotinib;Dasatinib
39 A Phase I Trial of Lenalidomide and Radiotherapy in Children With Diffuse Intrinsic Pontine Gliomas and High-grade Gliomas Completed NCT01222754 Phase 1 Lenalidomide
40 Cilengitide (EMD121974) in Combination With Irradiation in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma: Phase I Study Completed NCT01165333 Phase 1 Cilengitide dose escalation;Cilengitide
41 A Phase I Study of Motexafin Gadolinium (Xcytrin, NSC 695238) and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood Completed NCT00003909 Phase 1 motexafin gadolinium
42 A Phase I and Early Efficacy Study of Convection Enhanced Delivery of Irinotecan Liposome Injection Using Real Time Imaging With Gadolinium in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT03086616 Phase 1 Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)
43 ONC201 in Newly Diagnosed Diffuse Intrinsic Pontine Glioma and Recurrent/Refractory Pediatric H3 K27M Gliomas Recruiting NCT03416530 Phase 1 ONC201
44 A Phase I Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) With Temsirolimus in Children With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma (DIPG) Recruiting NCT02420613 Phase 1 Temsirolimus;Vorinostat
45 Abemaciclib in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma, and in Children With Recurrent and Refractory Solid Tumors Including Malignant Brain Tumors Recruiting NCT02644460 Phase 1 Abemaciclib
46 Phase I Study of GDC-0084, a Brain-Penetrant PI3 Kinase/mTOR Inhibitor, in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas After Radiation Therapy Recruiting NCT03696355 Phase 1 GDC-0084
47 Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma Recruiting NCT02717455 Phase 1 LBH589
48 Phase I Trial of DNX-2401 for Diffuse Intrinsic Pontine Glioma Newly Diagnosed in Pediatric Patients. Recruiting NCT03178032 Phase 1
49 Phase 1 Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors Recruiting NCT04185038 Phase 1
50 A Phase 1, Open-Label, Dose Escalation Study of CLR 131 in Children and Adolescents With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors Recruiting NCT03478462 Phase 1 CLR 131

Search NIH Clinical Center for Diffuse Intrinsic Pontine Glioma

Genetic Tests for Diffuse Intrinsic Pontine Glioma

Anatomical Context for Diffuse Intrinsic Pontine Glioma

MalaCards organs/tissues related to Diffuse Intrinsic Pontine Glioma:

40
Brain, Spinal Cord, Pons, Eye, T Cells, Testes, Bone

Publications for Diffuse Intrinsic Pontine Glioma

Articles related to Diffuse Intrinsic Pontine Glioma:

(show top 50) (show all 492)
# Title Authors PMID Year
1
Indolent course of brainstem tumors with K27M-H3.3 mutation. 61
31793190 2020
2
Biopsy in diffuse pontine gliomas: expert neurosurgeon opinion-a survey from the SIOPE brain tumor group. 61
32020269 2020
3
Longitudinal Monitoring of Gd-DTPA Following Convection Enhanced Delivery in the Brainstem. 61
32028001 2020
4
A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study. 61
32009149 2020
5
Radiation dose response of neurologic symptoms during conformal radiotherapy for diffuse intrinsic pontine glioma. 61
32016716 2020
6
Clinical trials for diffuse intrinsic pontine glioma: the current state of affairs. 61
31489454 2020
7
Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care. 61
31896081 2020
8
Hypofractionated radiotherapy in children with diffuse intrinsic pontine glioma. 61
31785177 2020
9
Characterizing the pharmacokinetics of panobinostat in a non-human primate model for the treatment of diffuse intrinsic pontine glioma. 61
31894347 2020
10
Deformational changes after convection-enhanced delivery in the pediatric brainstem. 61
31896089 2020
11
A New Treatment Opportunity for DIPG and Diffuse Midline Gliomas: 5-ALA Augmented Irradiation, the 5aai Regimen. 61
31963414 2020
12
Hypofractionated radiotherapy with temozolomide in diffuse intrinsic pontine gliomas: a randomized controlled trial. 61
31728883 2020
13
An atypical presentation of diffuse midline pontine glioma in a middle age patient: Case report. 61
31548089 2020
14
MRI Patterns of Extrapontine Lesion Extension in Diffuse Intrinsic Pontine Gliomas. 61
31974084 2020
15
Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG. 61
31940975 2020
16
Modeling DIPG in the mouse brainstem. 61
31907541 2020
17
Evaluating infusate parameters for direct drug delivery to the brainstem: a comparative study of convection-enhanced delivery versus osmotic pump delivery. 61
31896090 2020
18
3-O-ethyl-l-ascorbic acid: Characterisation and investigation of single solvent systems for delivery to the skin. 61
31517290 2019
19
Diffuse intrinsic pontine gliomas: Diagnostic approach and treatment strategies. 61
31870682 2019
20
Retrospective analysis on the consistency of MRI features with histological and molecular markers in diffuse intrinsic pontine glioma (DIPG). 61
31848724 2019
21
Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. 61
31588023 2019
22
Aberrantly expressed microRNAs and their implications in childhood central nervous system tumors. 61
31797180 2019
23
A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors. 61
31876107 2019
24
The 100 most-cited articles about diffuse intrinsic pontine glioma: a bibliometric analysis. 61
31203394 2019
25
The intersect of neurosurgery with diffuse intrinsic pontine glioma. 61
31786541 2019
26
Pediatric diffuse intrinsic pontine glioma: where do we stand? 61
31802357 2019
27
Oncohistone Mutations in Diffuse Intrinsic Pontine Glioma. 61
31813457 2019
28
Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets. 61
31464759 2019
29
Proton therapy for newly diagnosed pediatric diffuse intrinsic pontine glioma. 61
31728705 2019
30
Defining Optimal Target Volumes of Conformal Radiation Therapy for Diffuse Intrinsic Pontine Glioma. 61
31785339 2019
31
Signal Transduction in Diffuse Intrinsic Pontine Glioma. 61
31328874 2019
32
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. 61
31631026 2019
33
TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG). 61
31481512 2019
34
Increasing value of autopsies in patients with brain tumors in the molecular era. 61
31571114 2019
35
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. 61
31456142 2019
36
Pediatric Brainstem Gliomas: An Institutional Experience. 61
31903354 2019
37
Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma. 61
31488577 2019
38
Fostering open collaboration in drug development for paediatric brain tumours. 61
31551357 2019
39
A pilot precision medicine trial for children with diffuse intrinsic pontine glioma-PNOC003: A report from the Pacific Pediatric Neuro-Oncology Consortium. 61
30861105 2019
40
Generation of diffuse intrinsic pontine glioma mouse models by brainstem targeted in utero electroporation. 61
31638150 2019
41
ACVR1 Function in Health and Disease. 61
31683698 2019
42
Diagnostics and treatment of diffuse intrinsic pontine glioma: where do we stand? 61
31522324 2019
43
Radiosensitization by Histone H3 Demethylase Inhibition in Diffuse Intrinsic Pontine Glioma. 61
31227500 2019
44
Liquid biopsy for diffuse intrinsic pontine glioma: an update. 61
31491754 2019
45
A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival. 61
31324890 2019
46
Treatment options for paediatric brainstem gliomas. 61
31511736 2019
47
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. 61
31439867 2019
48
Robot-assisted stereotactic brainstem biopsy in children: prospective cohort study. 61
30523502 2019
49
Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. 61
31201162 2019
50
DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas. 61
30943283 2019

Variations for Diffuse Intrinsic Pontine Glioma

ClinVar genetic disease variations for Diffuse Intrinsic Pontine Glioma:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 BRCA2 NM_000059.3(BRCA2):c.4474_4477AAAG[1] (p.Glu1493fs)short repeat Pathogenic 51653 rs80359454 13:32912965-32912968 13:32338828-32338831
2 BRIP1 NM_032043.2(BRIP1):c.1045G>C (p.Ala349Pro)SNV Likely pathogenic 30535 rs149364097 17:59878709-59878709 17:61801348-61801348
3 CHEK2 NM_007194.4(CHEK2):c.1100del (p.Thr367fs)deletion Conflicting interpretations of pathogenicity 128042 rs555607708 22:29091857-29091857 22:28695869-28695869
4 NF1 NM_000267.3(NF1):c.1888G>A (p.Val630Ile)SNV Uncertain significance 220148 rs751795238 17:29552155-29552155 17:31225137-31225137

Expression for Diffuse Intrinsic Pontine Glioma

Search GEO for disease gene expression data for Diffuse Intrinsic Pontine Glioma.

Pathways for Diffuse Intrinsic Pontine Glioma

Pathways related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 20)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 H3C2 H3C1 H3-3B H3-3A
2
Show member pathways
13.13 H3C2 H3C1 H3-3B H3-3A
3
Show member pathways
13.12 H3C2 H3C1 H3-3B H3-3A
4
Show member pathways
13.08 H3C2 H3C1 H3-3B H3-3A
5
Show member pathways
13.01 H3C2 H3C1 H3-3B H3-3A BRCA2
6
Show member pathways
12.94 H3C2 H3C1 H3-3B H3-3A
7
Show member pathways
12.77 H3C2 H3C1 H3-3B H3-3A
8
Show member pathways
12.67 H3C2 H3C1 H3-3B H3-3A
9
Show member pathways
12.66 H3C2 H3C1 H3-3B H3-3A
10
Show member pathways
12.54 H3C2 H3C1 H3-3B H3-3A
11
Show member pathways
12.36 H3C2 H3C1 H3-3B H3-3A
12 12.08 H3C2 H3C1 H3-3B H3-3A
13
Show member pathways
11.97 H3C2 H3C1 H3-3B H3-3A
14 11.89 H3C2 H3C1 H3-3B H3-3A
15 11.75 H3C2 H3C1 H3-3B H3-3A
16
Show member pathways
11.55 H3C2 H3C1 H3-3B H3-3A
17
Show member pathways
11.49 H3C2 H3C1 H3-3B H3-3A BRCA2
18
Show member pathways
11.41 H3C2 H3C1 H3-3B H3-3A
19 11.07 H3-3B H3-3A
20 10.98 H3C2 H3C1

GO Terms for Diffuse Intrinsic Pontine Glioma

Cellular components related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.83 H3C2 H3C1 H3-3B H3-3A BRCA2
2 extracellular region GO:0005576 9.78 H3C2 H3C1 H3-3B H3-3A
3 extracellular exosome GO:0070062 9.76 H3C2 H3C1 H3-3B H3-3A
4 protein-containing complex GO:0032991 9.65 H3C2 H3C1 H3-3B H3-3A BRCA2
5 chromosome GO:0005694 9.62 H3C2 H3C1 H3-3B H3-3A
6 nuclear chromosome, telomeric region GO:0000784 9.58 H3-3B H3-3A BRCA2
7 nucleosome GO:0000786 9.46 H3C2 H3C1 H3-3B H3-3A
8 Barr body GO:0001740 9.37 H3-3B H3-3A
9 nuclear chromosome GO:0000228 9.26 H3C2 H3C1 H3-3B H3-3A
10 nuclear nucleosome GO:0000788 8.92 H3C2 H3C1 H3-3B H3-3A

Biological processes related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 spermatogenesis GO:0007283 9.8 H3-3B H3-3A BRCA2
2 brain development GO:0007420 9.74 H3-3B H3-3A BRCA2
3 cellular protein metabolic process GO:0044267 9.73 H3C2 H3C1 H3-3B H3-3A
4 cell proliferation GO:0008283 9.72 H3-3B H3-3A BRCA2
5 blood coagulation GO:0007596 9.71 H3C2 H3C1 H3-3B H3-3A
6 nucleosome assembly GO:0006334 9.67 H3C2 H3C1 H3-3B H3-3A
7 osteoblast differentiation GO:0001649 9.65 H3-3B H3-3A
8 male gonad development GO:0008584 9.65 H3-3B H3-3A
9 spermatid development GO:0007286 9.64 H3-3B H3-3A
10 multicellular organism growth GO:0035264 9.64 H3-3B H3-3A
11 positive regulation of cell growth GO:0030307 9.63 H3-3B H3-3A
12 single fertilization GO:0007338 9.63 H3-3B H3-3A
13 response to hormone GO:0009725 9.62 H3-3B H3-3A
14 regulation of gene silencing by miRNA GO:0060964 9.62 H3C2 H3C1 H3-3B H3-3A
15 protein heterotetramerization GO:0051290 9.61 H3C2 H3C1
16 embryo implantation GO:0007566 9.61 H3-3B H3-3A
17 oogenesis GO:0048477 9.6 H3-3B H3-3A
18 DNA replication-dependent nucleosome assembly GO:0006335 9.59 H3C2 H3C1
19 interleukin-7-mediated signaling pathway GO:0038111 9.58 H3C2 H3C1
20 nucleus organization GO:0006997 9.58 H3-3B H3-3A
21 DNA replication-independent nucleosome assembly GO:0006336 9.56 H3-3B H3-3A
22 regulation of megakaryocyte differentiation GO:0045652 9.56 H3C2 H3C1 H3-3B H3-3A
23 muscle cell differentiation GO:0042692 9.54 H3-3B H3-3A
24 regulation of gene silencing GO:0060968 9.52 H3C2 H3C1
25 pericentric heterochromatin assembly GO:0031508 9.51 H3-3B H3-3A
26 regulation of centromere complex assembly GO:0090230 9.49 H3-3B H3-3A
27 negative regulation of chromosome condensation GO:1902340 9.48 H3-3B H3-3A
28 telomeric heterochromatin assembly GO:0031509 9.46 H3-3B H3-3A
29 negative regulation of gene expression, epigenetic GO:0045814 9.46 H3C2 H3C1 H3-3B H3-3A
30 chromatin silencing at rDNA GO:0000183 9.26 H3C2 H3C1 H3-3B H3-3A
31 telomere organization GO:0032200 8.92 H3C2 H3C1 H3-3B H3-3A

Molecular functions related to Diffuse Intrinsic Pontine Glioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA binding GO:0003677 9.35 H3C2 H3C1 H3-3B H3-3A BRCA2
2 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.32 H3-3B H3-3A
3 nucleosomal DNA binding GO:0031492 9.26 H3-3B H3-3A
4 RNA polymerase II core promoter sequence-specific DNA binding GO:0000979 9.16 H3-3B H3-3A
5 protein heterodimerization activity GO:0046982 8.92 H3C2 H3C1 H3-3B H3-3A

Sources for Diffuse Intrinsic Pontine Glioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....